218 related articles for article (PubMed ID: 34668637)
1. Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.
Webb J; Mount J; von Arx LB; Rachman J; Spanopoulos D; Wood R; Tritton T; Massey O; Idris I
Diabetes Obes Metab; 2022 Feb; 24(2):289-295. PubMed ID: 34668637
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study.
Romera I; Artime E; Ihle K; Díaz-Cerezo S; Rubio de-Santos M; de Prado A; Cebrián-Cuenca A; Conget I
Adv Ther; 2022 Aug; 39(8):3589-3601. PubMed ID: 35689162
[TBL] [Abstract][Full Text] [Related]
3. Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists.
Sciannameo V; Berchialla P; Orsi E; Lamacchia O; Morano S; Querci F; Consoli A; Avogaro A; Fadini GP;
Diabetes Obes Metab; 2020 May; 22(5):817-827. PubMed ID: 31943710
[TBL] [Abstract][Full Text] [Related]
4. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Boye KS; Riddle MC; Gerstein HC; Mody R; Garcia-Perez LE; Karanikas CA; Lage MJ; Riesmeyer JS; Lakshmanan MC
Diabetes Obes Metab; 2019 Jun; 21(6):1299-1304. PubMed ID: 30714309
[TBL] [Abstract][Full Text] [Related]
5. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
Am J Manag Care; 2018 Apr; 24(8 Suppl):S146-S155. PubMed ID: 29693361
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
Nauck MA; Quast DR
Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
[TBL] [Abstract][Full Text] [Related]
8. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
Verma S; McGuire DK; Bain SC; Bhatt DL; Leiter LA; Mazer CD; Monk Fries T; Pratley RE; Rasmussen S; Vrazic H; Zinman B; Buse JB
Diabetes Obes Metab; 2020 Dec; 22(12):2487-2492. PubMed ID: 32744418
[TBL] [Abstract][Full Text] [Related]
9. Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
Verma S; Fainberg U; Husain M; Rasmussen S; Rydén L; Ripa MS; Buse JB
Diabetes Obes Metab; 2021 Jul; 23(7):1677-1680. PubMed ID: 33606902
[TBL] [Abstract][Full Text] [Related]
10. Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials.
Kang YM; Cho YK; Lee J; Lee SE; Lee WJ; Park JY; Kim YJ; Jung CH; Nauck MA
Diabetes Metab J; 2019 Aug; 43(4):410-421. PubMed ID: 30604598
[TBL] [Abstract][Full Text] [Related]
11. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(S8 Suppl 1):19-30. PubMed ID: 32756221
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
13. Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
Husain M; Consoli A; De Remigis A; Pettersson Meyer AS; Rasmussen S; Bain S
Cardiovasc Diabetol; 2022 Apr; 21(1):64. PubMed ID: 35484580
[TBL] [Abstract][Full Text] [Related]
14. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
16. Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus.
Cai X; Ji L
Diabetes Ther; 2021 Jul; 12(7):1861-1870. PubMed ID: 34047959
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.
Boyle JG; Livingstone R; Petrie JR
Clin Sci (Lond); 2018 Aug; 132(15):1699-1709. PubMed ID: 30115742
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.
Varin EM; McLean BA; Lovshin JA
Can J Diabetes; 2020 Feb; 44(1):68-77. PubMed ID: 31699625
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide.
MacIsaac RJ
Future Cardiol; 2021 May; 17(3):459-473. PubMed ID: 33820430
[TBL] [Abstract][Full Text] [Related]
20. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials.
Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I
Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
